NCT02567786

Brief Summary

Coagulation abnormalities after pediatric open-heart surgery are complex and very often multifactorial. Besides the cardiopulmonary bypass (CPB), the congenital pathology and the coagulation tests during CPB, the younger age has been the most significant risk factor for bleeding and transfusion requirements. In children the volume of pump priming is much higher compared with the patient's circulating blood volume. For this reason the CPB tubing system is primed with packed red blood cells and fresh frozen plasma (FFP) to avoid excessive hemodilution and induced coagulopathy. While this is routinely performed in neonates and small infants, the routine priming of CPB system with FFP has been questioned in several randomized prospective studies in older infants. However, the results of these studies are conflicting. Moreover, they show methodological issues.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Oct 2015

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 29, 2015

Completed
2 days until next milestone

Study Start

First participant enrolled

October 1, 2015

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 5, 2015

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2018

Completed
1 day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2018

Completed
Last Updated

December 5, 2018

Status Verified

December 1, 2018

Enrollment Period

2.7 years

First QC Date

September 29, 2015

Last Update Submit

December 4, 2018

Conditions

Outcome Measures

Primary Outcomes (2)

  • Postoperative bleeding (mL blood in the chest tubes). Significant postoperative bleeding is defined as a bleeding of > 5ml/kg/h in the first 6hours postoperatively.

    The exact amount of blood loss in the postoperative period per kilogram weight of child.

    The first 6 hours postoperatively

  • Increased risk of of donor exposure intraoperatively and postoperatively.

    The total number of different packs of allogeneic blood products administered per child.

    The first 6 hours postoperatively

Secondary Outcomes (2)

  • Volume of transfused allogenic blood products (mL).

    The first 6 hours postoperatively

  • Comparison of Rotem and Multiplate between both groups.

    The first 6 hours postoperatively

Study Arms (2)

Fresh Frozen Plasma

ACTIVE COMPARATOR

The priming of the CPB oxygenator will be done with 15 ml/kg of FFP in addition to packed red blood cells.

Procedure: Surgery with CPBOther: Fresh Frozen Plasma

Plasmalyte

ACTIVE COMPARATOR

The priming of the CPB oxygenator will be done with 15 ml/kg of Plasmalyte in addition to packed red blood cells.

Procedure: Surgery with CPBOther: Plasmalyte

Interventions

Fresh Frozen PlasmaPlasmalyte
Fresh Frozen Plasma
Plasmalyte

Eligibility Criteria

Age2 Months - 70 Months
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Children weighing between 7 and 15 kg and admitted to undergo open-heart surgery with CPB

You may not qualify if:

  • Patients with preoperative coagulation abnormalities
  • Parental refusal
  • Emergency surgery
  • Patients with preoperative renal or hepatic dysfunction

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mona Momeni

Brussels, 1200, Belgium

Location

MeSH Terms

Conditions

Heart Defects, Congenital

Interventions

Surgical Procedures, OperativePlasmalyte A

Condition Hierarchy (Ancestors)

Cardiovascular AbnormalitiesCardiovascular DiseasesHeart DiseasesCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Officials

  • Mona Momeni, MD,PhD

    Université Catholique de Louvain; Cliniques Universitaires Saint Luc

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Professor

Study Record Dates

First Submitted

September 29, 2015

First Posted

October 5, 2015

Study Start

October 1, 2015

Primary Completion

June 30, 2018

Study Completion

July 1, 2018

Last Updated

December 5, 2018

Record last verified: 2018-12

Locations